NewswireToday - /newswire/ -
Nottingham, United Kingdom, 2010/03/24 - Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, announces new data which demonstrates extended shelf life of protein drug products using Recombumin, recombinant human albumin.
The data, presented for the first time at a recent protein-focused industry event, reveals the potential for Recombumin to reduce product loss by preventing the physical and chemical degradation of protein drugs.
A data sheet entitled "Recombumin®: A pharmaceutical excipient in the stabilization of therapeutic protein products" details the findings. The study investigated the ability of Recombumin, a recombinant human albumin expressed in Saccharomyces cerevisiae, to prevent the deterioration of protein drug products in a variety of test formulations. The study particularly addressed Recombumin's minimization of surface adsorption, oxidation and aggregation in comparison to excipients commonly used for the purpose of formulating protein drugs.
The new data demonstrates that Recombumin has the capacity to improve the shelf life of protein drug products. The study's findings indicate that Recombumin performed as well as and often better than the comparators making it an effective multi-purpose excipient with the capability to reduce the total number of excipients required and therefore simplifying the formulation strategy.
Derived from Novozymes Biopharma's proprietary yeast expression technology, Recombumin is the world's leading animal-free, commercially available recombinant human albumin used in the manufacture of licensed and developmental human therapeutics. Offering the stabilizing benefits of albumin in a GMP compliant and regulatory package, Recombumin ensures high performance and security of long term supply. Its compliance with the excipient monograph for recombinant human albumin published in the United States Pharmacopoeia - National Formulary (USP-NF) also eases the regulatory process for customers and sets the industry benchmark for recombinant human albumin.
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.
Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.